CSPC PHARMA (01093) saw its shares rise more than 3%. As of the time of writing, the stock was up 3.39%, trading at HK$9.15, with a turnover of HK$297 million.

On the news front, as of January 5th, the latest announcement on the official website of China's Center for Drug Evaluation (CDE) showed that the New Drug Application for Empagliflozin Tablets, submitted by CSPC PHARMA's wholly-owned subsidiary CSPC Ouyi Pharmaceutical Co., Ltd. under chemical drug registration category 4, has been accepted for review.

Public information indicates that Empagliflozin Tablets, as a Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitor, are primarily used to treat type 2 diabetes, heart failure, and chronic kidney disease.

Developed by Germany's Boehringer Ingelheim and co-promoted with Eli Lilly, Empagliflozin is an SGLT2 inhibitor drug.

As one of the top three SGLT2 inhibitors globally, Empagliflozin has become a star drug in the diabetes treatment field due to its unique glucose-lowering mechanism and cardiovascular and renal protective effects.

In recent years, the sales scale of Empagliflozin Tablets has expanded rapidly across China's three major terminal markets and six key market segments, notably reaching a milestone of 1 billion yuan in 2024 and achieving a year-on-year growth of nearly 20% in the first quarter of 2025.